GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actelion Ltd (OTCPK:ALIOF) » Definitions » Institutional Ownership

Actelion (Actelion) Institutional Ownership : 4.17% (As of May. 06, 2024)


View and export this data going back to . Start your Free Trial

What is Actelion Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Actelion's institutional ownership is 4.17%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Actelion's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Actelion's Float Percentage Of Total Shares Outstanding is 0.00%.


Actelion Institutional Ownership Historical Data

The historical data trend for Actelion's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Actelion Institutional Ownership Chart

Actelion Historical Data

The historical data trend for Actelion can be seen below:

2015-06-30 2015-09-30 2015-12-31 2016-03-31 2016-06-30 2016-09-30 2016-12-31 2017-03-31 2017-06-30 2017-09-30
Institutional Ownership 34.91 35.88 34.94 38.08 36.65 34.46 25.44 11.04 0.97 4.17

Actelion Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Actelion (Actelion) Business Description

Traded in Other Exchanges
N/A
Address
Actelion is a Swiss biopharmaceutical firm with several products on the market, largely focused on pulmonary arterial hypertension: Tracleer, Opsumit, Uptravi, Ventavis, and Veletri treat various stages of the disease via different methods of administration. Zavesca is a second-line option for Gaucher disease, and Valchlor treats a rare form of blood cancer. Actelion has created a global commercial infrastructure for its approved orphan drugs and has supplemented its internal pipeline through in-licensing and acquisitions.

Actelion (Actelion) Headlines

From GuruFocus

Eaton Vance Worldwide Health Sciences Fund 4th Quarter Commentary

By Holly LaFon Holly LaFon 01-24-2017

Actelion Still On Growth Track

By reports.droy reports.droy 02-18-2015

Jean Hynes Reduces Stake in Actelion

By Kyle Ferguson Kyle Ferguson 08-03-2016

Eaton Vance Worldwide Health Sciences Fund 4th Quarter Commentary

By Holly LaFon Holly LaFon 02-14-2017